PharmAust (ASX:PAA) has announced a protocol deviation in its trial of Monepantel (MPL) for treating motor neurone disease.
The principal investigator has recommended that the stable patient should be elected from cohort one to cohort two and received the associated increase in MPL dosage.
The company said it expects that the patient will be moved to cohort four with the other cohort two patients, subject to safety committee approval.
PharmAust Executive Chairman Dr Roger Aston said, “Under the flexible protocol and based on advice from the Principal Investigator, we are implementing a protocol deviation to allow transfer of a patient from Cohort 1 to Cohort 2, with the associated increase in the dosage of MPL. The absence of any material adverse events in Cohort 1 to date is highly encouraging as is the potential stability associated with the patient being transferred to Cohort 2."